Tetrahedron Letters 50 (2009) 1642–1644

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

Selective synthesis of Neu5Ac2en and its oxazoline derivative using $BF_3{\cdot}Et_2O$

Goreti Ribeiro Morais, Rudi Santiago Oliveira, Robert A. Falconer *

Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, Bradford BD7 1DP, UK

ARTICLE INFO

Article history:
Received 19 November 2008
Revised 9 January 2009
Accepted 23 January 2009
Available online 27 January 2009

Keywords:
Lewis acid
$BF_3{\cdot}Et_2O$
Sialic acid
Glycal
Neu5Ac2en
Oxazoline

ABSTRACT

Application of the Lewis acid $BF_3{\cdot}Et_2O$ to the selective synthesis of 5-acetamido-2,6-anhydro-3,5-dideoxy-D-*glycero*-D-*galacto*-non-2-enonic acid (Neu5Ac2en) and the related oxazoline, methyl 7,8,9-tri-*O*-acetyl-2,3,4,5-tetradeoxy-2,3-didehydro-2,3-trideoxy-4′,5′-dihydro-2′-methyloxazolo[5,4-*d*]- D-*glycero*-D-talo-non-2-enonate is described.

N-Acetylneuraminic acid **1a** (sialic acid, Neu5Ac, Fig. 1) is commonly found on the surface of mammalian cells and is of particular importance in cellular recognition processes, cell adhesion and disease states.[1] Hence there is great interest in the synthesis of sialosides, either as biological probes or as enzyme inhibitors. Many of the procedures to obtain such analogues proceed through the intermediate 2-chlorosialic acid **2** (Fig. 1), but a disadvantage to its use is competitive elimination of the chlorine atom, which is aided by the electron-withdrawing nature of the protected carboxylic acid at the 2-position. This commonly leads to the formation of a 2-deoxy-2,3-dehydro-Neu5Ac derivative (Neu5Ac2en **3a**, Fig. 1). Neu5Ac2en and its *N*-glycolyl analogue are metabolic products found in body fluids and secretions[2] and as a result are of interest *per se*. Neu5Ac2en[3] is a potent sialidase inhibitor, as are analogues modified at C-4.[4–6] It has been used as the basis for the design and synthesis of sialidase inhibitors with anti-influenza activity,[7–9] the best example being Zanamivir (4-guanidino-Neu5Ac2en). In addition, inhibition of other sialidases has been achieved by z2,3-unsaturated analogues.[10–12] Chemically, per-*O*-acetylated 2,3-unsaturated sialic acid derivative **3b** has been used for the preparation of analogues of sialic acid via the epoxide,[13–16] synthesis of *N*-acetyl-3-fluoroneuraminic acid by treatment of the glycal **3b** with $X_2Fe{-}BF_3{\cdot}Et_2O$,[17] molecular fluorine[18] or TEDA–$CH_2Cl{\cdot}2BF_4$ (Selectfluor)[19] and for the synthesis of C-4 substituted sialic acid analogues via the 4,5-oxazoline derivative **4**.

Typically, the preparation of **3b** involves the base-promoted elimination of 2-chlorosialoside **2**, using bases such as DBU,[13,20,21] anhydrous H_2PO_4 in refluxing MeCN[22] and pyridine.[16] In addition, one group has reported the synthesis of **3b** from per-*O*-acetyl methyl ester **1c** when treated with $PPh_3{\cdot}HBr$ in MeCN.[19] The respective 4-epimer can be readily prepared from methyl ester **1b** when treated with Ac_2O in H_2SO_4 at 80 °C,[10,23] or from the 2-bromosialic acid derivative when treated with *syn*-collidine.[20]

Also of importance is the corresponding 2,3-unsaturated 4,5-oxazoline derivative **4**, particularly in the synthesis of C-4 modified sialosides.[4,7,24] Compound **4** is prepared easily by the Lewis acid-promoted internal nucleophilic attack of the acetamido group (lone pair of the oxygen) on the electrophilic centre at the 4-position with inversion of configuration. Two different strategies have



1a R^1=H; R^2=H (Neu5Ac)
1b R^1=Me; R^2=H
1c R^1=Me; R^2=Ac

2

3a R^1=H; R^2=H (Neu5Ac2en)
3b R^1=Me; R^2=Ac

4

Figure 1.

* Corresponding author. Tel.: +44 1274 235842; fax: +44 1274 233234.
E-mail address: r.a.falconer1@bradford.ac.uk (R.A. Falconer).

0040-4039/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2009.01.117

been reported in the literature: (a) synthesis of the 4,5-oxazoline **4** from the Neu5Ac2en per-*O*-acetate **3b** using $BF_3{\cdot}Et_2O$[25] or $SnCl_4$[26] and (b) synthesis of the 4,5-oxazoline **4** from per-*O*-acetylated sialic acid **1c**, using trimethylsilyl trifluoromethanesulfonate (TMSOTf) as the catalyst.[4,6,27]

The chemical scope of oxazoline **4** is diverse. Catalytic hydrogenation (Pd/C) produces the respective 4-deoxy Neu5Ac2en derivative[4] whereas acidic cleavage by trifluoroacetic acid gives the 4-*epi*-Neu5Ac2en derivative.[4] This 4-*epi*-Neu5Ac2en has been prepared previously by refluxing Neu5Ac with sulfuric acid and acetic anhydride.[10] Nucleophiles have also been introduced to this molecule, for example, sulfur and nitrogen at C-4; the oxazoline ring was opened stereoselectively via an S_N2 reaction to obtain the 4-α diastereomer.[25] 2,3-Unsaturated derivatives were also synthesised by acetolysis of β-methyl glycosides of sialic acid in a one-pot reaction using Ac_2O in concentrated sulfuric acid with further hydrolysis to the 4-*epi*-acetate or 4-*epi*-hydroxy derivative at pH 5 and pH 2, respectively.[28] Recently, a 3,4-unsaturated sialic acid derivative was prepared via a Lewis acid-catalysed Ferrier reaction of the activated allylic oxazoline **4**.[29]

Our attempts to prepare a *C*-allyl-sialoside directly from the per-*O*-acetate using $BF_3{\cdot}Et_2O$, in a manner similar to that reported with aldoses,[30] resulted in a mixture of products with an olefinic hydrogen. Prompted by this finding, a series of experiments were carried out to investigate the effect of $BF_3{\cdot}Et_2O$ on sialic acid derivative **1c** in the absence of a nucleophile (Scheme 1). Conditions were varied, including equivalents of $BF_3{\cdot}Et_2O$, reaction times and solvents (Table 1). Interestingly, selectivity as to the formation of either per-*O*-acetylated Neu5Ac2en **3b** or the 2,3-unsaturated 4,5-oxazoline sialic acid **4** could be achieved according to the solvent used. Performing the reaction in acetonitrile resulted in 2,3-unsaturated sialic acid **3b** whereas use of dichloromethane led almost exclusively to 2,3-unsaturated 4,5-oxazoline sialic acid **4** (entries 2 and 3). It was found that selectivity was both time and temperature dependent. By monitoring the reaction using ^1H NMR spectroscopy, it was observed that reaction times longer than 1.5 h increased the proportion of **4** (decreasing the ratio of **3b**:**4**) in dichloromethane. Compound **4** was selectively formed when the reactions were carried out in dichloromethane overnight. It was found that 1.2 equiv of the Lewis acid $BF_3{\cdot}Et_2O$ was sufficient to complete the reaction (entry 5). Fewer equivalents of $BF_3{\cdot}Et_2O$ led to a slight increase in formation of compound **4** (entry 7) and incomplete conversion (entry 8). In contrast, compound **1c** was completely converted to **3b** after 1.5 h when the reaction was carried out in acetonitrile at 25 °C (entry 3). As a comparison, the reactions were also attempted using $SnCl_4$, which produced a ratio of **3b**:**4** of 1:1 over a similar reaction time. $BF_3{\cdot}Et_2O$ clearly delivers a significantly higher degree of selectivity.

In further experiments, we observed that reacting sialic acid methyl ester **1b** with $BF_3{\cdot}Et_2O$ and acetic anhydride also promoted formation of oxazoline **4**. It should be noted that these conditions were recently used in a similar manner for per-*O*-acetylated aldoses.[31] In this case, a mixture of **1c**, **3b** and **4** was obtained. Interestingly, an excess of Ac_2O led to that mixture whereas an excess of $BF_3{\cdot}Et_2O$ led to only **3b** and **4**, with a predominance of **4** (Scheme 2). The von Itzstein group has reported the synthesis of **4** in one step when treating 1-methylsialoside methyl ester with acetic anhydride using TMSOTf as catalyst, but the use of $BF_3{\cdot}Et_2O$ led only to peracetylation and no elimination product was observed.[28]

Table 1

1c $\xrightarrow[\text{overnight}]{\text{Lewis acid}}$ **3b** + **4**

Entry	Lewis acid	Equivalents	Solvent	Yield[a] (%)	Ratio **3b**:**4**[b]
1	$BF_3{\cdot}Et_2O$	6.0	CH_2Cl_2	93	1:99
2	$BF_3{\cdot}Et_2O$	3.0	CH_2Cl_2	74	1:99
3	$BF_3{\cdot}Et_2O$	3.0	CH_3CN[c]	92	9:1
4	$BF_3{\cdot}Et_2O$	3.0	CH_2Cl_2[c]	51	5:1
5	$BF_3{\cdot}Et_2O$	1.2	CH_2Cl_2	95	1:99
6	$BF_3{\cdot}Et_2O$	1.0	CH_2Cl_2[d]	ND	2:3
7	$BF_3{\cdot}Et_2O$	1.0	CH_2Cl_2	98	1:5
8	$BF_3{\cdot}Et_2O$	0.5[e]	CH_2Cl_2	56	1:4
9	$SnCl_4$	1.2	CH_3CN	91	1:1

ND—not determined.
[a] Total isolated yield of **3b** + **4**.
[b] Ratio determined by ^1H NMR.
[c] 1.5 h, 25 °C.
[d] 4.5 h, rt.
[e] 7.5% of starting material was recovered.

The structural assignment of **4** was aided by data reported in the literature.[10] It should be noted that the coupling constant between H-4 and H-5 changes from 2.5 to approximately 9 Hz on formation of the oxazoline ring. In addition, the double doublet attributed to H-6 is shielded by the oxazoline ring and is therefore shifted to higher field (δ 3.41).

It is believed that the stability of the oxazoline **4** is limited, showing a high susceptibility to ring opening and consequent formation of C-4 substituted analogues. Thus, the preparation of oxazoline **4** directly from methyl ester **1b** or from the per-*O*-acetate sialic acid **1c** to obtain Neu5Ac2en derivatives is a significant advantage, given that transformations such as hydrogenation, halogenation or oxidations have been shown to have drawbacks when carried out with Neu5Ac2en itself.

In summary, the Lewis acid $BF_3{\cdot}Et_2O$ can be utilised to selectively prepare Neu5Ac2en **3b** or the related oxazoline **4**, depending on the conditions used. Acetonitrile affords Neu5Ac2en per-acetate **3b** whereas dichloromethane affords oxazoline **4** (Scheme 1). The methodology to synthesise Neu5Ac2en **3b**, in particular, offers significant advantages over published methods involving chlorosialoside **2**.

*Synthesis of methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-*D*-glycero-*D*-talo-non-2-enonate* (Neu5Ac2en, **3b**):[13,32] $BF_3{\cdot}Et_2O$ (72 μL, 0.57 mmol) was added to a solution of methyl 5-acetamido-2,4,7,8,9-penta-*O*-acetyl-3,5-dideoxy-D-*glycero*-D-*galacto*-2-α/β-nonulopyranosonate (100 mg, 0.19 mmol) in



Scheme 1.



1b 3b 4

Scheme 2.

dry acetonitrile (2 mL) under a nitrogen atmosphere at 25 °C. After 90 min, the reaction mixture was diluted with dichloromethane (25 mL) and $NaHCO_3$ powder was added. The reaction mixture was filtered and concentrated to give **3b** (quant.).

*Synthesis of methyl 7,8,9-tri-O-acetyl-2,3,4,5-tetradeoxy-2,3-didehydro-2,3-trideoxy-4′,5′-dihydro-2′-methyloxazolo[5,4-d]-*D*-glycero-*D*-talo-non-2-enonate* (**4**):[10,33] $BF_3{\cdot}Et_2O$ (29 μL, 0.23 mmol) was added to a solution of methyl 5-acetamido-2,4,7,8,9-penta-*O*-acetyl-3,5-dideoxy-D-*glycero*-D-*galacto*-2-α/β-nonulopyranosonate (100 mg, 0.19 mmol) in dry dichloromethane (2 mL) under a nitrogen atmosphere at room temperature. After stirring overnight, the reaction mixture was diluted with dichloromethane (25 mL) and $NaHCO_3$ powder was added. The reaction mixture was filtered and concentrated to give **4** (77 mg, 95%).

Acknowledgements

This work was supported by EPSRC (GRM) and Yorkshire Cancer Research (RAF). The authors thank Andrew Healey for running low resolution mass spectra.

References and notes

1. Reutter, W. K. E.; Bauer, C.; Gerok, W.. In *Cell Biology Monographs*; Schauer, R., Ed.; Springer-Veilag: Vienna, 1982; Vol. 1, pp 263–305.
2. Schauer, R. K. S.; Reuter, G.; Roggentin, P.; Shaw, L. In *Biochemistry and Role of Sialic Acids*; Rosenberg, A., Ed.; Plenum Press: New York, 1995; pp 7–49.
3. Meindl, P. T. H. *Monatsch. Chem.* **1969**, 1295–1306.
4. Schreiner, E.; Zbiral, E.; Kleineidam, R. G.; Schauer, R. *Liebigs Ann. Chem.* **1991**, 129–134.
5. Zbiral, E.; Brandstetter, H. H.; Christian, R.; Schauer, R. *Liebigs Ann. Chem.* **1987**, 781–786.
6. Lu, Y.; Gervay-Hague, J. *Carbohydr. Res.* **2007**, *342*, 1636–1650.
7. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. *Nature* **1993**, *363*, 418–423.
8. Bamford, M. J.; Pichel, J. C.; Husman, W.; Patel, B.; Storer, R.; Weir, N. G. *J. Chem. Soc., Perkin Trans. 1* **1995**, 1181–1187.
9. Smith, P. W.; Starkey, I. D.; Howes, P. D.; Sollis, S. L.; Keeling, S. P.; Cherry, P. C.; von Itzstein, M.; Wu, W. Y.; Jin, B. *Eur. J. Med. Chem.* **1996**, *31*, 143–150.
10. Kumar, V.; Kessler, J.; Scott, M. E.; Patwardhan, B. H.; Tanenbaum, S. W.; Flashner, M. *Carbohydr. Res.* **1981**, *94*, 123–130.
11. Miller, C. A.; Wang, P.; Flashner, M. *Biochem. Biophys. Res. Commun.* **1978**, *83*, 1479–1487.
12. Chong, A. K. J.; Pegg, M. S.; Taylor, N. R.; von Itzstein, M. *Eur. J. Biochem.* **1992**, *207*, 335–343.
13. Okamoto, K.; Kondo, T.; Goto, T. *Bull. Chem. Soc. Jpn.* **1987**, *60*, 631–636.
14. Okamoto, K.; Kondo, T.; Goto, T. *Bull. Chem. Soc. Jpn.* **1987**, *60*, 637–643.
15. Hinou, H.; Sun, X. L.; Ito, Y. *Tetrahedron Lett.* **2002**, *43*, 9147–9150.
16. Sun, X. L.; Kanie, Y.; Guo, C. T.; Kanie, O.; Suzuki, Y.; Wong, C. H. *Eur. J. Org. Chem.* **2000**, 2643–2653.
17. Petrie, C. R.; Sharma, M.; Simmons, O. D.; Korytnyk, W. *Carbohydr. Res.* **1989**, *186*, 326–334.
18. Nakajima, T.; Hori, H.; Ohrui, H.; Meguro, H.; Ido, T. *Agric. Biol. Chem.* **1988**, *52*, 1209–1215.
19. Burkart, M. D.; Vincent, S. P.; Wong, C. H. *Chem. Commun.* **1999**, 1525–1526.
20. Byramova, N. E.; Tuzikov, A. B.; Bovin, N. V. *Carbohydr. Res.* **1992**, *237*, 161–175.
21. Gregar, T. Q.; Gervay-Hague, J. *J. Org. Chem.* **2004**, *69*, 1001–1009.
22. Kulikova, N. Y.; Shpirt, A. M.; Kononov, L. O. *Synthesis* **2006**, 4113–4114.
23. Sato, K.; Ikeda, K.; Suzuki, T.; Aoyama, S.; Maki, N.; Suzuki, Y.; Sato, M. *Tetrahedron* **2007**, *63*, 7571–7581.
24. Li, J.; Zheng, M. Y.; Tang, W.; He, P. L.; Zhu, W. L.; Li, T. X.; Zuo, J. P.; Liu, H.; Jiang, H. L. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5009–5013.
25. von Itzstein, M.; Jin, B.; Wu, W. Y.; Chandler, M. *Carbohydr. Res.* **1993**, *244*, 181–185.
26. Kumar, V.; Tanenbaum, S. W.; Flashner, M. *Carbohydr. Res.* **1982**, *101*, 155–159.
27. Schmid, W.; Christian, R.; Zbiral, E. *Tetrahedron Lett.* **1988**, *29*, 3643–3646.
28. Kok, G. B.; Groves, D. R.; von Itzstein, M. *Chem. Commun.* **1996**, 2017–2018.
29. Ikeda, K.; Ueno, Y.; Kitani, S.; Nishino, R.; Sato, M. *Synlett* **2008**, 1027–1030.
30. Giannis, A.; Sandhoff, K. *Tetrahedron Lett.* **1985**, *26*, 1479–1482.
31. Tiwari, P.; Agnihotri, G.; Misra, A. K. *J. Carbohydr. Chem.* **2005**, *24*, 723–732.
32. *Compound* **3b**:[13] ^{1}H NMR ($CDCl_3$) δ 1.90 (s, 3H, NAc), 2.01, 2.02, 2.05, 2.09 (4s, 12H, 4OAc), 3.77 (s, 3H, COOMe), 4.17 (dd, 1H, H-9a, $J_{8,9a}$ = 6.9 Hz, $J_{9a,9b}$ = 12.3 Hz), 4.35–4.38 (m, 2H), 4.57 (dd, 1H, H-9b, $J_{8,9b}$ = 3.4 Hz, $J_{9a,9b}$ 12.3 Hz), 5.33–5.34 (m, 1H), 5.42–5.34 (m, 2H), 5.58 (m, 1H), 5.98 (d, 1H, ^3J 2.7 Hz); ESI MS $C_{20}H_{27}O_{12}N$ (473.15) *m/z* 474 $[M+H]^+$, 496 $[M+Na]^+$.
33. *Compound* **4**:[10] ^{1}H NMR ($CDCl_3$) δ 1.99, 2.04, 2.04, 2.14 (4s, 12H, 3OAc and CH_3), 3.41 (dd, 1H, H-6, $J_{6,7}$ = 2.5 Hz, $J_{5,6}$ = 9.9 Hz), 3.79 (s, 3H, COOMe), 3.93 (dd, 1H, H-5, $J_{4,5}$ = 8.7 Hz, $J_{5,6}$ = 9.9 Hz), 4.22 (dd, 1H, H-9a, $J_{8,9a}$ = 6.3 Hz, $J_{9a,9b}$ = 12.5 Hz), 4.58 (dd, 1H, H-9b, $J_{8,9a}$ 2.5 Hz, $J_{9a,9b}$ = 12.5 Hz), 4.81 (dd, 1H, H-4, $J_{3,4}$ = 3.9 Hz, $J_{4,5}$ = 8.7 Hz), 5.53 (ddd, 1H, H-8, $J_{8,9a}$ = 2.5 Hz, $J_{6,7}$ = 6.0 Hz, $J_{8,9a}$ = 6.3 Hz), 5.62 (dd, 1H, H-7, $J_{6,7}$ = 2.5 Hz, $J_{6,7}$ = 6.0 Hz), 6.37 (d, 1H, H-3, $J_{3,4}$ = 3.9 Hz); ESI MS $C_{18}H_{23}NO_{10}$ (413.38) *m/z* 414 $[M+H]^+$.